- TV Footage
- Financial Reports
- Newsletter Overview
- Social Media
- Media Contact
Monheim, July 27, 2018 – Bayer will appeal against the recent ruling of the General Court of the European Union in Case T-429/13. The company is concerned that the verdict, announced in May, could have far-reaching consequences for the certainty and predictability of active substance approvals in the European Union (EU). By appealing against the verdict, Bayer aims to ensure that some general interpretations of the crop protection law established by the court are re-considered. These interpretations may have importance beyond this particular case, and Bayer believes they are not legally founded.
Bayer wishes to underline that it respects the European legislative process and accepts the recent decision of the EU Member States to broadly restrict the use of certain neonicotinoids in agriculture. As a consequence, the company has withdrawn the clothianidin dossier from the ongoing renewal process.
Bayer stands by the safety of its products – which have been approved by regulatory bodies around the globe – and reiterates the value that neonicotinoids have for farmers in managing pests effectively.
Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of 35.0 billion euros. Capital expenditures amounted to 2.4 billion euros, R&D expenses to 4.5 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.